Capricor Therapeutics (NASDAQ:CAPR) Director Sells $1,667,397.05 in Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Director Karimah Es Sabar sold 53,735 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $31.03, for a total transaction of $1,667,397.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Karimah Es Sabar also recently made the following trade(s):

• On Thursday, April 2nd, Karimah Es Sabar sold 7,529 shares of Capricor Therapeutics stock. The stock was sold at an average price of $32.00, for a total transaction of $240,928.00.
• On Tuesday, March 31st, Karimah Es Sabar sold 61,265 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.17, for a total transaction of $1,848,365.05.

Capricor Therapeutics Price Performance

Shares of NASDAQ CAPR opened at $32.11 on Friday. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of -14.21 and a beta of 0.48. Capricor Therapeutics, Inc. has a 52-week low of $4.30 and a 52-week high of $40.37. The business’s 50 day moving average is $27.38 and its two-hundred day moving average is $19.10.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). Analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on CAPR shares. Wall Street Zen downgraded Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. UBS Group set a $50.00 price target on shares of Capricor Therapeutics in a research report on Monday, December 15th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday, March 10th. Piper Sandler reaffirmed an “overweight” rating and set a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Finally, Oppenheimer increased their target price on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $46.09.

Institutional Investors Weigh In On Capricor Therapeutics

Large investors have recently bought and sold shares of the stock. Creek Drive Management Group LLC acquired a new stake in Capricor Therapeutics in the 4th quarter valued at about $1,039,000. SB Capital Management Inc acquired a new position in shares of Capricor Therapeutics during the fourth quarter worth about $11,544,000. Ikarian Capital LLC grew its position in shares of Capricor Therapeutics by 118.4% during the fourth quarter. Ikarian Capital LLC now owns 578,015 shares of the biotechnology company’s stock worth $16,682,000 after buying an additional 313,373 shares in the last quarter. Virtus Investment Advisers LLC increased its stake in shares of Capricor Therapeutics by 25.2% during the fourth quarter. Virtus Investment Advisers LLC now owns 10,224 shares of the biotechnology company’s stock worth $295,000 after buying an additional 2,061 shares during the period. Finally, Susquehanna Portfolio Strategies LLC acquired a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $384,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Trending Headlines about Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Several brokerages have raised targets or issued overweight/buy ratings (Cantor Fitzgerald $62, Piper Sandler $58, Maxim $50), supporting upside expectations versus the consensus.
• Neutral Sentiment: One director sale (7,529 shares at $32.00) was executed under a pre‑arranged Rule 10b5‑1 plan, which typically mutes the negative signal from insider selling but does not eliminate market concern. SEC Filing
• Neutral Sentiment: Institutional ownership is modest (~21.7%) with a few small new positions reported — indicates some institutional interest but not large-scale conviction yet. Institutional Holdings
• Negative Sentiment: CFO Anthony Bergmann sold 25,000 shares on March 31 at an average $30.13 (disclosed in an SEC Form 4), reducing his direct holding by ~75% — a sizable insider reduction that may worry investors about near-term outlook or personal liquidity needs. CFO Sale Filing
• Negative Sentiment: Director Karimah Es Sabar sold large blocks across March 31–April 1–2 (61,265 @ $30.17; 53,735 @ $31.03; plus a 7,529 @ $32.00 sale under a 10b5‑1 plan). Combined insider disposals this week total roughly 148k shares for several million dollars — a significant decrease in insider ownership that can pressure sentiment. Director Sale Filing
• Negative Sentiment: Capricor missed Q4 EPS estimates (reported -$0.62 vs. consensus -$0.51 on March 12), which is a near-term fundamental negative that analysts and investors will weigh against bullish price targets. Earnings Report

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.